Full Press Release Details
MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia.
MBX
MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Key Takeaway: MBX Biosciences Announces Positive Topline Results from Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Price reaction · baseline $16.28 (2025-01-06 close) · hit after-hours · clean, no other MBX news in the window
day 0 close
-10.3%
day 1
-10.9%
day 3 · peak
-23.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+163%
120-day peak, hindsight
Typical move
5.3%
average across 7 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
MBX 4291
Phase 1 · Obesity